Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis.

ABSTRACT: Background/Objectives: Glecaprevir/pibrentasvir (G/P) and elbasvir/grazoprevir (EBR/GZR) are effective treatments for chronic hepatitis C (CHC), especially in patients with chronic kidney disease (CKD). However, both regimens carry a risk of drug-induced liver injury (DILI). This study investigates the association between renal failure and DILI, using real-world data, and assesses the effectiveness of these treatments in peritoneal dialysis patients. Methods: A retrospective cohort study was conducted using data from the Ditmanson Research Database, including patients with CHC treated with G/P or EBR/GZR from 1 August 2017 to 31 December 2020. Patients were categorized into CKD and normal kidney function (NKF) groups. Two sensitivity analyses were performed to assess DILI ris

SUBMITTER: Hung HY 

PROVIDER: S-EPMC11760478 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature